- Home
- KNRX vs AEON Comparison
KNRX vs AEON Comparison
Compare KNRX & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNRX | AEON |
|---|---|---|
| Founded | 2009 | N/A |
| Country | Singapore | United States |
| Employees | N/A | 8 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 13.0M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KNRX | AEON |
|---|---|---|
| Price | $1.17 | $0.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 26.4K | ★ 7.4M |
| Earning Date | 06-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.18 |
| 52 Week High | $3.45 | $1.45 |
Technical Indicators
Market Signals| Indicator | KNRX | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 89.37 | 49.03 |
| Support Level | $0.35 | $0.24 |
| Resistance Level | $1.46 | $0.33 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 75.71 | 23.64 |
Price Performance
Historical ComparisonAbout KNRX KNOREX LTD. Class A Ordinary Shares
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service, enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.